These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 26667309)
1. Recent advances in vaccine delivery. Cordeiro AS; Alonso MJ Pharm Pat Anal; 2016; 5(1):49-73. PubMed ID: 26667309 [TBL] [Abstract][Full Text] [Related]
2. Controlled delivery of antigens and adjuvants in vaccine development. Zhao Z; Leong KW J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136 [TBL] [Abstract][Full Text] [Related]
3. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. Chatzikleanthous D; O'Hagan DT; Adamo R Mol Pharm; 2021 Aug; 18(8):2867-2888. PubMed ID: 34264684 [TBL] [Abstract][Full Text] [Related]
4. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines. Jin Z; Gao S; Cui X; Sun D; Zhao K Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213 [TBL] [Abstract][Full Text] [Related]
5. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature. Mrsny RJ J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692 [TBL] [Abstract][Full Text] [Related]
6. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Gupta RK; Chang AC; Siber GR Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260 [TBL] [Abstract][Full Text] [Related]
7. Nanovaccines : nanocarriers for antigen delivery. Gonzalez-Aramundiz JV; Cordeiro AS; Csaba N; de la Fuente M; Alonso MJ Biol Aujourdhui; 2012; 206(4):249-61. PubMed ID: 23419252 [TBL] [Abstract][Full Text] [Related]
8. Biphasic lipid vesicles as a subcutaneous delivery system for protein antigens and CpG oligonucleotides. Alcón VL; Baca-Estrada ME; Potter A; Babiuk LA; Kumar P; Foldvari M Curr Drug Deliv; 2006 Apr; 3(2):129-35. PubMed ID: 16610999 [TBL] [Abstract][Full Text] [Related]
9. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624 [TBL] [Abstract][Full Text] [Related]
10. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Wang S; Liu H; Zhang X; Qian F Protein Cell; 2015 Jul; 6(7):480-503. PubMed ID: 25944045 [TBL] [Abstract][Full Text] [Related]
11. Immunity in response to particulate antigen-delivery systems. Storni T; Kündig TM; Senti G; Johansen P Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945 [TBL] [Abstract][Full Text] [Related]
12. Mucosal delivery of vaccine antigens and its advantages in pediatrics. De Magistris MT Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335 [TBL] [Abstract][Full Text] [Related]
13. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery. Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762 [TBL] [Abstract][Full Text] [Related]